|
|
There
is a need for new formulations of effective protease
inhibitors with lower pill burdens. Convenient dosing
increases compliance and thus efficacy.
|
|
Objective
|
This study
is investigating if optimized (lower pill burden)
Viracept™-based HAART will result in a non-detectable
viral load.
|
|
|
Volunteers
will all receive the same dosing of medication.
No
volunteer will receive placebo.
|
Inclusion
Criteria
(partial
list)
|
•
HIV+ adult male or female
•
Viral
load > 2000 copies/ml
•
T-cells
> 200
•
No prior anti-HIV therapy
|
|
Status
__
|
Enrolling
--
|
For
more information about participating in this study
in the Los Angeles area, please call 310.358.2429
or e-mail Corie Castro at
ccastro@aidsresearch.org
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS ReSearch Alliance
Institutional Review Board in October, 2003.
|
